Grants per year
- 225 - 250 out of 1,105 results
Search results
-
A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination with Tremelimumab in Patients with Metastatic HER2 Negative Breast Cancer
Cristofanilli, M., Santa-Maria, C. A. & Blanco Jr, L. Z.
Avon Products Foundation, Inc.
1/1/16 → 12/31/18
Project: Research project
-
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer
Purdue University, National Institute of Biomedical Imaging and Bioengineering
1/1/16 → 4/30/18
Project: Research project
-
Targeting Ovarian Cancer Stem Cells through Selective Inhibition of ALDH1A1
Matei, D. E. & Condello, S.
Indiana University-Purdue University Indianapolis, National Cancer Institute
1/1/16 → 6/30/18
Project: Research project
-
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer (#T2013-003B)
V Foundation for Cancer Research
1/1/16 → 12/31/17
Project: Research project
-
Development of novel therapeutics for the treatment of human glioblastoma
Mazar, A. P., James, C. D., Raizer, J. J. & Ugolkov, A.
Northwestern Memorial Hospital
1/1/16 → 12/31/17
Project: Research project
-
-
Prot #MK-3475-164-02: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma
Merck Sharp & Dohme Corporation
12/16/15 → 12/16/18
Project: Research project
-
Prot #NEOD001-CL002: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis
Covance Inc., Prothena Therapeutics Limited
12/11/15 → 12/11/18
Project: Research project
-
Prot #EMR 100070-001: A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors a
Kircher, S. M. & Nimeiri, H. S.
Quintiles, Inc., EMD Serono, Inc.
12/10/15 → 12/10/21
Project: Research project
-
The Role of ZEB1 Mutations in Cutaneous T Cell Lymphoma
Choi, J., Crispino, J. D. & Shilatifard, A.
12/8/15 → 6/30/20
Project: Research project
-
Prot #EZH-202: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Agulnik, M.
12/7/15 → 12/7/21
Project: Research project
-
Prot #INCB 52793-101: A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Karmali, R. & Kaplan, J. B.
12/2/15 → 12/2/18
Project: Research project
-
Treating cognitive impairments in cancer patients via systematic light exposure
Wu, L. M., Mehta, J., Mroczek, D. K., Penedo, F. J. & Zee, P. C.
11/20/15 → 10/16/19
Project: Research project
-
Prot #MK-3475-062-00: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Tre
Merck Sharp & Dohme Corporation
11/18/15 → 11/18/21
Project: Research project
-
Prot #ABI-007-ST-001: A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or
PPD Development, Celgene Corporation
11/11/15 → 11/11/18
Project: Research project
-
Prot #MK-3475-061-02: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and F
Merck Sharp & Dohme Corporation
10/29/15 → 10/29/21
Project: Research project
-
Prot #54767414MMY3010: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to
Janssen Research & Development, LLC
10/23/15 → 10/23/18
Project: Research project
-
Prot #TPU-TAS-102-109: A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination with CPT-11 and Bevacizumab in Patients with Advanced Gastrointestinal Tumors
Medpace, Inc., Taiho Oncology, Inc.
10/16/15 → 10/16/18
Project: Research project
-
Prot #INCB 53914-101: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Kaplan, J. B.
10/8/15 → 10/8/18
Project: Research project
-
Prot #PNT2258-04-Richter's (Brighton): A Phase II Study Of PNT2258 in Patients with Richter's Transformation (RT)
Kaplan, J. B.
10/2/15 → 10/2/18
Project: Research project
-
VA IPA for Elspeth Beauchamp
Platanias, L. C. & Beauchamp, E. M.
10/1/15 → 7/31/19
Project: Research project
-
Role of Cohesin Mutations in Acute Myelogenous Leukemia
Crispino, J. D.
10/1/15 → 9/30/17
Project: Research project
-
Avon Foundation for Breast Cancer Research and Care Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Platanias, L. C., Bulun, S. E., Gius, D. R., Khan, S. A., Wang, J. & Zhao, H.
Avon Products Foundation, Inc.
10/1/15 → 9/30/17
Project: Research project